The Democratic Republic of the Congo’s Ebola outbreak caused by Bundibugyo virus has reached 808 confirmed cases and 192 confirmed deaths, the World Health Organization reported on June 16, 2026, in Disease Outbreak News DON607—a figure based on data through June 15. The count covers cases across Ituri province (738 confirmed), North Kivu (67 confirmed), and South Kivu (3 confirmed), spanning 31 health zones.
Uganda, which recorded 19 confirmed cases and 2 confirmed deaths among imported cases since the outbreak began, has reported no new confirmed cases since June 10, a six-day stretch of silence that health officials are monitoring cautiously. One additional probable case with a fatal outcome has been recorded in Uganda.
WHO Director-General Tedros Adhanom Ghebreyesus determined the outbreak constitutes a Public Health Emergency of International Concern (PHEIC) on May 17, 2026, under Article 12 of the International Health Regulations. The IHR Emergency Committee convened May 19 and issued temporary recommendations to member states on May 22.
The outbreak’s pathogen, Bundibugyo virus (BDBV), is one of six known Ebola species. It is a critical distinction: the approved vaccines and several targeted therapeutics were developed against Zaire ebolavirus, not Bundibugyo. No licensed vaccine exists for the Bundibugyo strain, leaving supportive care as the primary intervention available at scale.
That gap makes Wednesday’s WHO announcement all the more consequential. On June 17, 2026, WHO released what it describes as its first comprehensive clinical management guidelines for filovirus disease, covering all Ebola strains and Marburg virus. The document sets out 16 evidence-based recommendations developed through global expert consultations and grounded in lessons from recent Ebola and Marburg outbreaks. Central themes include early intravenous fluid resuscitation, management of shock with vasoactive agents, prompt antibiotic therapy for secondary bacterial infections, laboratory monitoring for metabolic complications, and structured survivor follow-up. WHO says early supportive care can significantly improve survival even where curative treatments are unavailable.
For European public health agencies, the outbreak’s scale raises questions about cross-border risk—though current estimates place that risk very low. The European Centre for Disease Prevention and Control modeled the probability of at least one Bundibugyo virus importation into the EU or European Economic Area during the June 11–25 window at 0.45% (90% uncertainty interval: 0.20%–0.85%). That translates to roughly one importation per 23,000 travelers from the primary outbreak zones in North Kivu and Ituri—a figure ECDC notes is likely an overestimate given reduced air traffic from those regions.
The outbreak trajectory and the absence of a licensed BDBV vaccine underscore why the new WHO guidelines are being received as urgent rather than merely timely. For clinicians in Ituri’s treatment units, sixteen evidence-based recommendations may now be the sharpest tool available.